Summary
Fourty-four evaluable patients were treated with 6-methylmercaptopurine riboside (MMPR) at a dose of 20 mg/m2/day x 5 by continuous IV infusion (days 1–5) and 5-fluorouracil (5-FU) on an escalating dose schedule of 300–1519 mg/m2/day x 5 by continuous IV infusion (days 2–6). Dose-limiting oral mucositis occured at a 5-FU dose of 1,381 mg/m2/day; other toxicities included nausea, vomiting, diarrhea, skin rash, and occasional myelosuppression. A partial and a complete response were observed in two previously untreated patients with metastatic colon carcinoma given the highest 5-FU doses (1,381 and 1,519 mg/m2/day). Bone marrow phosphoribosyl pyrophosphate (PRPP) levels monitored after 24 h of MMPR treatment indicated increases of 7.8- and 9.2-fold those found prior to therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ansfield F, Klotz J, Nealon T, Ramirez G, Minton J, Hill G, Wilson W, Hugh D (1977) A phase III study comparing the clinical utility of four regiments of 5-fluorouracil. Cancer 39:34–40
Bedikian TT, Stroehlein JR, Karlin DA, Bennets RW, Bodey GP, Valdiviseo M (1981) Chemotherapy for colorectal cancer with a combination of PALA and 5-FU. Cancer Treat Rep 65:747–753
Cadman E, Heimer R, Davis L (1979) Enhanced 5-fluorouracil nucleotide formation following methotrexate: biochemical explanation for drug synergism. Science 205:1135–1137
Casper ES, Vale D, Williams LJ, Martin DS, Young CW (1983) Phase I and clinical immunologic evaluation of biochemical modulation of 5-fluorouracil with N-(phosphonacetyl)-l-asparatic acid. Cancer Res 43:2324–2329
Horton J, Olson KB, Sullivan J, Reily C, Schnider B (1970) 5-Fluorouracil in cancer: an improved regimen. Ann Intern Med 73:897–900
Kornberg A, Liebermann I, Simms E (1955) Enzymatic synthesis of 5-phosphoribosylpyrophosphate. J Biol Chem 215:389–402
Kufe DW, Egan EM (1981) Enhancement of 5-fluorouracil incorporation into human lymphoblast ribonucleic acid. Biochem Pharmacol 30:129–133
Kufe DW, Major PP (1981) 5-FU incorporation into human breast carcinoma correlates with cytotoxicity. J Biol Chem 256:9802–9805
Major P, Egan E, Sargent L, Kufe D (1982) Modulation of 5-FU metabolism in human MCF-7 breast carcinoma cells. Cancer Chemother Pharmacol 8:87–91
Martin DS, Stolfi RL, Sawyer RC, Nayak R, Spiegelman S, Schmid F, Heimer R, Cadman E (1981) Biochemical modulation of 5-fluorouracil and cytosine arabinoside with emphasis on thymidine, PALA and 6-methylmercaptopurine riboside. In: Nucleotides and Cancer Treatment. Academic Press, Sydney, pp 382–399
Moyer J, Handschumacher R (1979) Selective inhibition of pyrimidine synthesis and depletion of nucleotide pools by N-(phosphonacetyl)-l-asparate. Cancer Res 39:3089–3094
Seifert P, Baker LH, Reed ML, Vaitkevicius VK (1975) Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal cancer adenocarcinoma. Cancer 36:123–128
Spiegelman S, Nayak R, Sawyer R, Stolfi R, Martin D (1980) Potentiation of the anti-tumor activity of 5-FU thymidine and its correlation with the formation of (5-FU)RNA. Cancer 45:1129–1134
Weiss GR, Ervin TJ, Meshad MW, Kufe DW (1982) A phase II trial of combination therapy with continuous infusion N-(phosphonacetyl)-l-asparate and bolus infusion 5-fluorouracil. Cancer Treat Rep 66:299–303
Weiss GR, Ervin TJ, Meshaed MW, Shade D, Branfman AR, Bruni RJ, Chadwick M, Kufe DW (1982) A phase I trial of combination therapy with continuous-infusion PALA and continuous-infusion 5-FU. Cancer Chemother Pharmacol 8:301–304
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Peters, W.P., Weiss, G. & Kufe, D.W. Phase-I trial of combination therapy with continuous-infusion MMPR and continuous-infusion 5-FU. Cancer Chemother. Pharmacol. 13, 136–138 (1984). https://doi.org/10.1007/BF00257131
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00257131